therapeutics

Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (“Monte Rosa”) (Nasdaq: GLUE), a clinical-stage biotechnology company developing…

2 days ago

Onco3R Therapeutics Appoints Lawrence Blatt as Chair of the Board for Onco3R Therapeutics

Leuven, Belgium. January 8, 2026. Onco3R Therapeutics, a clinical-stage immunology and oncology biotech company dedicated to transforming patients’ lives with…

3 days ago

Engitix Announces $25 Million Series A Extension Financing by Existing Investor Mike Platt to Advance ECM-Targeted Therapeutics in Solid Tumors and Fibrosis

Company has built one of the largest proprietary extracellular matrix (ECM) datasets spanning fibrosis and solid tumors January 08, 2026…

3 days ago

Day One Completes Acquisition of Mersana Therapeutics

Acquisition expands Day One’s pipeline with clinical-stage antibody drug conjugate (ADC) emiltatug ledadotin (Emi-Le) targeting rare cancer adenoid cystic carcinoma…

4 days ago

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

December 30, 2025 09:15 ET  | Source: Akari Therapeutics Plc TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) --…

2 weeks ago

Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics

December 28, 2025 19:00 ET  | Source: Transcenta PRINCETON, N.J. and HANGZHOU, China, Dec. 28, 2025 (GLOBE NEWSWIRE) -- Transcenta…

2 weeks ago

Biosplice Therapeutics Announces First Patient Dosed in InvestigatorInitiated Phase 1 Clinical Trial of Cirtuvivint and Olaparib in BRCA/HRD PlatinumResistant Ovarian Cancer

SAN DIEGO, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company advancing small-molecule inhibition of…

3 weeks ago

Rezubio Announces $20 Million Series A Financing to Advance the Membrane-Anchored Therapeutics Platform and Company Pipeline, with Lead Program in Obesity and Diabetes

ZHUHAI, China, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rezubio, a China-based biotechnology company founded by former Merck scientists, today announced…

3 weeks ago

Rakovina Therapeutics Management to Attend Partnering Meetings During JPM Week, January in San Francisco, California

VANCOUVER, British Columbia, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”),…

4 weeks ago

Starton Therapeutics to Present at Biotech Showcase 2026

Company Will Also Host 1x1 Investor Meetings at the 15th Annual LifeSci Partners Corporate Access Event from January 13-14th in…

4 weeks ago